EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Real‐World Study of Resectable NSCLC Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy be Recommended?

Ming Li iD, Hao Yin, Yue Jin, Hari B Keshava, Rongkui Luo, Mingxiang Feng, Fenghao Sun

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Ming Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Fellowship of China National Postdoctoral Program for Innovative Talents, Youth Foundation of "Outstanding Resident Physician" Clinical Postdoctoral Program in Zhongshan Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effect of postoperative adjuvant immune checkpoint inhibitor (ICI) therapy on survival outcomes in resectable non‐small cell lung cancer (NSCLC) patients who received neoadjuvant chemoimmunotherapy.

Methods

A retrospective cohort study was conducted at Zhongshan Hospital, Fudan University, from January 2019 to June 2024, including resectable NSCLC patients treated with neoadjuvant chemotherapy combined with ICIs. Pathological responses were assessed, and event‐free survival (EFS) and overall survival (OS) were compared between patients who received postoperative adjuvant ICI therapy and those who did not.

Results

Among the 186 patients included, 106 received adjuvant ICI therapy, while 80 did not. No significant differences in EFS or OS were observed between the two groups in patients who achieved pathological complete response (pCR) or major pathological response (MPR) (EFS: p = 0.282, OS: p = 0.330). In contrast, patients who did not achieve pCR or MPR experienced a significant improvement in EFS with adjuvant ICI therapy ( p = 0.004). An AI‐based decision tree model developed to predict the need for postoperative adjuvant immunotherapy demonstrated strong performance, with an accuracy of 85% and an area under the curve (AUC) of 0.82. Key predictors identified by the model included pathological response, age, clinical stage, and PD‐L1 expression.

Conclusions

Postoperative adjuvant ICI therapy significantly improves EFS in resectable NSCLC patients, especially in those without pCR or MPR. However, its effect on OS remains uncertain. These findings highlight the importance of personalized treatment strategies, with adjuvant ICI offering greater benefits for patients with incomplete pathological responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoadjuvant TherapyImmunotherapyImmune Checkpoint InhibitorsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedChemotherapy, AdjuvantAdult

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
  • National Medical Center, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Thoracic Surgery, Huai'an People's Hospital of Hongze District, Huai'an, China.
  • Department of Surgery, Division of Thoracic Surgery, Irvine School of Medicine, University of California, Irvine, California, USA.
  • Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Thoracic Surgery, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, China.

ORCID-Profile: Ming Li

Förderung

  • National Natural Science Foundation of China
  • Fellowship of China National Postdoctoral Program for Innovative Talents
  • Youth Foundation of "Outstanding Resident Physician" Clinical Postdoctoral Program in Zhongshan Hospital
  • Fujian Provincial Natural Science Foundation, General Program
  • Natural Science Foundation of Fujian Province

Zitieren

APA

Li, M., Yin, H., Jin, Y., Keshava, H. B., Luo, R., Feng, M., & Sun, F. (2025). A Real‐World Study of Resectable NSCLC Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy be Recommended?. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70195

Vancouver

Li M, Yin H, Jin Y, Keshava HB, Luo R, Feng M, et al. A Real‐World Study of Resectable NSCLC Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy be Recommended?. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70195

BibTeX
@article{Li2025,
  author = {Li, Ming and Yin, Hao and Jin, Yue and Keshava, Hari B and Luo, Rongkui and Feng, Mingxiang and Sun, Fenghao},
  title = {A Real‐World Study of Resectable NSCLC Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy be Recommended?},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70195}
}
Kostenlos starten →